Summary Using a cell line derived from the VM spontaneous murine astrocytoma, a reliable in vitro-in vivo model of human malignant glioma has been developed. In this paper we examine the effects of cytotoxic drugs with known activity against other animal brain tumour models and human disease on the in vivo VM model. The drugs BCNU, CCNU and vincristine produced significant volume reduction in tumours growing at a subcutaneous location in syngeneic animals. Procarbazine was ineffective. Similarly, BCNU, CCNU and vincristine produced small but statistically significant increases in survival of VM mice bearing the intracerebral tumour, but procarbazine was again ineffective. The modest, but significant, response of the VM model to the nitrosoureas mimics the human situation more closely than previously described animal models.
A cell line VMDk 497-P(1), derived from the VM spontaneous murine astrocytoma (Fraser, 1980) , has been used to develop an in vitro-in vivo model of human glioma. The cell line can be grown as monolayer cultures and as multicellular tumour spheroids (Bradford et al., 1989a) . It also produces tumours at subcutaneous and intracranial sites when inoculated into syngeneic VM mice. In a previous report (Bradford et al., 1989b) we described the development of the in vivo model and showed that cell line 497-P(1) provides the basis for a reliable and reproducible model of glioma, which fulfils many of the criteria required for experimental therapy.
In this paper we describe the response of subcutaneous and intracranial tumours produced by VMDk 497-P(1) cells to treatment with BCNU, CCNU, vincristine (VCR) and procarbazine (PCB). These agents were chosen because their activity against human malignant glioma (Green et al., 1983) and other animal brain tumour models has been documented.
Materials and methods

Cell lines
The 497-P(I) cells are a derivative (Bradford et al., 1989a ) of a cell line, VMDk P497, the gift of Dr D. Bigner (Duke University Medical Center, Durham, North Carolina, USA). Cells were maintained in culture by methods previously described by Pilkington et al. (1983) . VM mice were bred at the Institute of Neurology and were the descendents of six breeding pairs supplied by Dr H. Fraser (ARC and MRC Neuropathogenesis Unit, Edinburgh).
Drug toxicity This was determined in non tumour-bearing animals. The LD50 was determined for BCNU, CCNU, VCR and PCB using the method described by Thompson (1947) and by reference to published tables (Weil, 1952) . Drugs were administered by i.p. injection in a total volume of 0.01 ml g-' body weight. For each drug four groups of four animals were dosed at levels spaced by a geometric factor of two. The mortality in each group was recorded at 30 days. In accordance with the observations of others (Shapiro & Basler, 1979) it was not possible to determine a reliable LD50 for PCB. The dosage schedules for this drug were therefore based on previous reports (Geran et al., 1974; Bradley et al., 1983; . For BCNU, CCNU and VCR, tumour-bearing animals were dosed with 0.5 of the calculated LD5,.
Chemotherapy of subcutaneous tumours On day 0 VM mice were inoculated subcutaneously with 106 497-P(l) cells harvested immediately beforehand from a nearconfluent monolayer culture. Bilateral inoculations were performed in order to minimise the number of animals used to achieve statistical significance (Warenius et al., 1980 Subcutaneous tumours were measured on day 6, on each day during the treatment period and thereafter two or three times weekly. On each occasion the width, length and depth of the tumour were recorded. Using these measurements, the tumour mass was expressed as a volume by substituting in a previously reported weight equation (Steel, 1977) The number of individual tumours regressing to a tumour volume less than the volume at the start of treatment was determined and expressed as a fraction of the total number of treated tumours. The ratio of the mean treated tumour to the mean control tumour volume (T/C) on day 21 was determined. Mean growth delay (GD) was measured by the method described by Houghton and Houghton (1983) Chemotherapy of intracerebral tumours VM mice were inoculated intracerebrally with 497-P(1) cells in the manner previously described (Pilkington et al., 1985; Bradford et al., 1989b ILS=(T/C)x 100% ILS values from experiments which were performed on two separate occasions were averaged to yield the mean increased life-span. An ILS of 25% was considered as indicative of activity (Geran et al., 1974) . Survival times of treated and control were compared using the Wilcoxon rank-sum test.
Results
Chemotherapy of subcutaneous tumours
In the course of these experiments 110 subcutaneous inoculations were performed, resulting in 102 tumours (93%). Control groups consisted of at least 10 tumours. The growth curve of untreated tumours is Gompertzian in form and the volume doubling time is approximately 1.4 days and 5.1 days at small and large volumes respectively (Bradford et al., 1989b) . The complete results are shown in Table I. BCNU Eight tumours were treated with a single dose of 30 mg kg-' BCNU on day 10 following inoculation. All eight tumours regressed in size from the initial treatment volume. Tumour regression was, however, transient and regrowth occurred between 2 and 3 days after treatment ( Figure 1 ). there was a significant volume reduction of treated tumours at day 21 with a TIC of 0.14. The mean growth delay to four times the treatment volume was 7.6 days. BCNU given as five successive daily doses of 6 mg kg-' also produced tumour regression in nine out of nine tumours ( Figure 1 ). Again tumour regression was transient and regrowth in eight of the nine tumours began before the end of the treatment schedule. Three tumours initially regrew at a more rapid rate than the pre-treatment growth rate. Both the TIC of 0.25 and the GD of 6.7 were smaller than those seen when the same dose of BCNU was given as a single injection.
CCNU Regression occurred in eight of nine and seven of 10 tumours treated with a single dose of 30 mg kg-' or five consecutive doses of 6 mg kg-' CCNU respectively. All tumours which regressed resumed growth within 2 or 3 days. Both schedules of CCNU produced significant volume reduction at day 21 although this was less than that observed for BCNU (Table I ). There was a marked difference in GD produced by the two schedules of CCNU. While a single dose of 30 mg kg-' produced a GD of 6.3 days, the GD for Although the use of tumours growing in extracerebral sites has been subject to much criticism, there has been renewed interest in the use of the subcutaneous model (Shapiro & Basler, 1979; . While intracerebral tumour models more closely resemble human brain tumours a subcutaneous model allows in vivo cellular sensitivity to be separated from any problems of drug delivery and the role of the blood-brain barrier and permits the rapid accumulation of serial quantitative data. In the present study the nitrosoureas BCNU and CCNU produced the greatest effect on subcutaneous tumours. VCR produced significant volume reduction at day 21, 7 days after the end of treatment, but did not produce consistent volume reduction with only four of nine tumours regressing. Growth delay produced by VCR was also modest. The variable response to VCR observed with this model is of interest. The greatest variability in in vitro chemosensitivity of the cloned cell lines derived from VMDk P497 (Koppel et al., 1987) was to the vinca alkaloids VCR and vindesine (Bradford et al., 1987) . The variability in response to VCR may reflect the different proportions of sensitive and resistant clonal subpopulations in 497-P(1) tumours. Variations in the proportions of VCR sensitive and resistant subpopulations may also influence the rapidity with which resistance to VCR can develop. It has been shown that this occurred rapidly when P497 intracerebral tumours were treated with VCR (Bradford et al., 1987) . PCB was ineffective at any dosage level. It is unlikely that the failure of response to PCB is due to inadequate dosage levels since some systemic toxicity did occur at the highest dose. It is more likely that there is inherent resistance of 497-P(1) cells to PCB, as has been seen in in vitro studies (Bradford et al., 1987 (Bradford et al., , 1988a .
The major emphasis of experimental chemotherapy of intracranial tumours has been on the effect of agents on prolongation of animal survival. Bigner and Swenberg (1979) have stated that ideally in an animal model of human glioma there should be significant increases in survival following treatment with the nitrosoureas. In the doses and schedules used in this study both BCNU and CCNU produced a significant extension of life, BCNU being marginally superior to CCNU. This demonstrates that clinically useful drugs are selected by the system. The optimal increases in ILS of 142.5% for BCNU and 132.5% for CCNU are, however, modest when compared to the results obtained with other animal models. In contrast to studies with the ependymoblastoma model (reviewed by Shapiro, 1974) no 'cures' were obtained. The most effective drug tested was CCNU. Single doses of between 30 and 50 mg kg-' regularly produced 80-90% cures when given on day 2 and a somewhat lower cure rate when given on days 7 and 14 following inoculation. BCNU was found to be less effective than CCNU, producing cures of 30-40% in the same kinds of schedules (Shapiro et al., 1970) . In the large study of Geran et al. (1974) BCNU produced 78% long-term survivors. It is important to note that these drugs very rarely produce cures in man.
A tumour model which is particularly chemosensitive, like the ependymoblastoma A (Geran et al., 1974) and glioma 26 (Levin et al., 1976) , is likely to overpredict the activity of some agents. The increase in survival of 497-P(1) tumourbearing mice produced by BCNU and CCNU is similar to that observed in the avian sarcoma virus induced glioma (Bigner et al., 1975) . The results from both these models closely parallel reports of nitrosourea treatment of human gliomas. Animal survival studies using the 9L model have shown that single LD1O doses of BCNU are at least as effective as up to one and a half times that amount given as divided doses (Rosenblum et al., 1983) . In the studies presented here, both BCNU and CCNU given as a single dose were marginally more effective in prolonging the life-span of VM mice than the equivalent given as five divided doses. Similar findings were also made by Geran et al. (1974) . Rosenblum et al. (1983) , using the 9L system and clonogenic cell survival studies, found that the administration of single large doses of BCNU resulted in the larger tumour cell kill, longer proliferation lag and slower repopulation rate than with smaller split doses. These data suggest that human treatment protocols should show greatest efficacy from the nitrosoureas when single large doses rather than fractionated schedules are used. A more recent study (Mbidde et al., 1988) has shown a small prolongation of survival, but no increase in the proportion of long-term survivors in patients with recurrent malignant glioma who were treated with high dose BCNU and autologous bone marrow rescue.
It is disappointing that this model does not respond to PCB, particularly in the light of its activity against human malignant glioma. Wilson (1978) has suggested that the failure of some animal models to respond to PCB may reflect differences in the metabolism of the drug between rodents and humans. This may be true for the rat but is unlikely to be so for the mouse because of the dramatic results obtained with PCB in other murine models (Geran et al., 1974; . Both in vitro and in vivo in this model of glioma PCB has consistently been the least effective agent used. This is probably due to the inherent cellular resistance of cell line 497-P(l) to PCB.
To date the VM glioma model has largely been used to confirm data already available from other animal models and from clinical studies. Its role in the future will be to predict the clinical efficacy of new therapies. It is currently being used to evaluate the effect of compounds for photodynamic therapy (Sandeman et al., 1987) and to screen a number of recently synthesised cytotoxic compounds.
